Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092557 | 0.87 | KDM4E (0.42) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL24784259 | 0.86 | ADRB2 (0.39) | KDM4ECYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL18908756 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL10914222 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL22930120 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908660 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908652 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL22837632 | 0.85 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL25827261 | 0.80 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL19263447 | 0.80 | HTT (0.33) | CYP1A2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | F5, OR10J3, SHBG | KDM4E 3362/4885CYP1A2 73/4885CYP2D6 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.